Printer Friendly

TRANSCATHETER DEVICE CLOSURE OF PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT FROM RIGHT VENTRICULAR APPROACH WITHOUT ARTERIOVENOUS LOOP.

Byline: Amjad Mehmood, Khurram Akhtar, Syeda Sadia Hina Kazmi, Mehboob Sultan, Nadim Sadiq, Aziz Ahmed, Hajira Akbar, Maad Ullah and Hafsa Inam

Keywords: Arteriovenous loop, Transcathter, Ventricular septal defect.

INTRODUCTION

The most common congenital heart defect encountered in pediatric cardiology clinic is VSD1. VSD may occur in isolation or it may be part of other cardiac anomalies or clinical syndromes2. Prevalence of VSD is about 25 to 30 percent. There are three main types of VSD namely, muscular, doubly committed and perimembranous, with perimembranous type the most common accounting for about 80 percent of the cases3. The natural course and clinical presentations of VSD are mostly dependent on VSD size. Children with large VSD may present early with clinical symptoms of tachypnea, feeding difficulties, failure to thrive, cardiac failure and even with pulmonary hypertension. These patients are diagnosed early. Children with small VSD may be diagnosed incidentally during clinical examination. Small VSD may close spontaneously with time and other may require intervention4.

Large VSD if left untreated may result in complications like ventricular dysfunction, aortic regurgitation and arrhythmias5. Management of this congenital defect has changed drastically in the last 5 decades Different modalities are used for VSD closure with each having advantages and disadvantages. Surgical closure of VSD has good short and long term outcome and at young age surgical VSD closure is still the best option. Long term survival after VSD closure is about 80 percent. Complications of surgical closure include arrhythmia, chylothoarx, aortic regurgitation and various degree heart blocks. Mortality from surgical closure at later stage is mostly due to cardiac causes like heart failure, sudden death and reoperation6. Transcatheter Closureof VSD isinnovative step in the curative management for this defect. Moreover transcatheter VSD Closure without arteriovenous loop is even more cost effective, timesaving, technically feasible and safe procedure.

Previously transcatheter closure of perimembranous VSD (PMVSD), whichinvolves the membranous andthe adjacent septum have been limited to small series with scaresresults7-9. However most of the studies focused on the closure ofmuscular septum, accounting for about 70% of cases. Conventional treatment for PMVSD is considered to beopen heart surgery with associated morbidity and mortality. From the advent of transcatheter VSD closure in 198810, this approach for VSD closure has been logical and scar free alternative to surgical closure which is even more favourable for young females for social and cosmetic reasons. Based on our local data in Pakistan, closures of PMVSD is done surgically with no reports of transcatheter occlusion11. This study was carried out to evaluate the safety and efficacy of transcatheter closure of PMVSD Without AV loop and to its short term outcome.

METHODOLOGY

From 02 Jan 2015 to 10 Oct 2018 Total 30 patients with PMVSD were enrolled for attempted transcatheter closure without AV Loop using the VSD occluders available at our centre. VSD occluder (shsma; Lipu Medical) and Occlutech VSD occluder were used in the study. In all PMVSD patients, transcatheter closure was indicated for large left to right shunt with pulmonary artery pressure not more than half systemic. Detailed Echocardiogram was done in each patient prior to the procedure. Estmation of VSD size and pulmonary artery presurewas carried out. All patients were routinely screened by conventional two-dimensional and colour Doppler transthoracic echocardiography (TTE).

The following inclusion criteria were used in this study: (i) congenital PMVSD as shown by echocardiography; (ii) body weight >10 kg and age >2 years; (iii) maximum VSD diameter 20 mm by TTE; (iv) defect located at the 9 to 11 o'clock positions of an analog clock in the short-axis parasternal view by TTE; (v) a distance of 1mm from the PMVSD to the aortic valve; (vi) left-to-right shunt; and (vii) calculated pulmonary vascular resistance <8 Wood units. The exclusion criteria are as follows: (i) defects associated with other cardiac lesions requiring a surgical approach; body-weight <10kg and age 8 Wood units; (ii) Aortic regurgitation; (iii) Aortic valve prolapse; and right-to-left shunt. Before intervention, an informed written consent was obtained from patients' Guardian/parents.

Physical examination, a chest X-ray, 12-lead electrocardiogram (ECG), and TTE were routinely performed toverify complete occlusion and to identify any new-onset aortic valve regurgitation. After the intervention, patients were transferred to the general wards. Continuous ECG monitoring was used during the first 24 hours after the procedure. Post procedural Aspirin (5 mg/kg) is givento all patients for 6 months. The catheterization procedure was performed under generalanaesthesia. Heparin (100 IU/kg) and antibiotics were administered intravenously during the procedure. Access was through the right femoral vein and artery. Angiography in the left ventricle at a 45/20 left anterior oblique projection/cranial was used to profile the PMVSD (fig-1). Location, size of the PMVSD, and its relationship with the aortic valve were assessed. Each PMVSD was categorized by shape as tubular, window-like, aneurysmal, or conical.

The diameter of the PMVSD was measured at the largest diastolic phase, and an occluder was selected based on this measurement. The defect was then passed from the right ventricle by a 5 FrJudkins right catheter (fig-2). After crossing the VSD, the catheter was replaced by super stiff exchange wire fig-3). A long sheath (6-12 Fr) was advanced to the left ventricle over this wire and positioned beneath the aortic valve preferably in the left ventricle apex. Through the long sheath, the pm VSD occluder was deployed under fluoroscopic control and echocardiographic guidance. Angiography in the left ventricle and ascending aorta was performed again to confirm adequate device implantation (fig-4 and 5). All patients were followed up until and the median follow-up period was 30 months. Clinical examination, Holter or electro-cardiographic monitoring, chest roentgenogram, and TTE were performed at 1, 6, 12 months after the procedure and yearly thereafter.

Adverse events were ascertained at each assessment on the basis of clinical evaluation. Thrombi, valve regurgitation, and residual shunts were looked for using TTE. Complications were prospectively recorded and divided into major and minor adverse events. Events were graded as major or minor adverse events. Major adverse events included but were not limited to death during or after the procedure because of complications of the procedure, complete heart block requiring pacemaker implantation, thromboembolism, and new-onset valvular regurgitation requiring surgical repair. Minor adverse events included but were not limited to groin haematoma, blood loss requiring transfusion, device embolization with transcatheter removal, any cardiac arrhythmia that required medication, new or increased valvular regurgitation less than two grades, haemolysis requiring medication, fever >38.5C, rash, and loss of peripheral pulse.

These minor adverse events required medical intervention but were not life threatening; they had no long-term sequelae and did not require long-term therapy. All the data was analyzed using SPSS Version 23. Frequency and percentages were calculated for qualitative variables like gender and VSD occluder devices and mean +- SD were calculated for quantitative variables like age, VSD size and VSD occluder size etc.

Table: Patient's data (quantitative variables) undergoing intervention.

Variables###Minimum###Maximum###Mean###Std. Deviation

Age (years)###2.00###18.00###7.1111###4.64878

VSD Size (mm)###3.50###7.00###4.8667###1.31719

Device Size###5###10###7.00###1.581

Flouroscopy time(min)###5###24###11.56###5.897

Procedure time(min)###15###35###24.44###6.346

Contrast used (mm)###40###120###81.67###28.723

RESULTS

Among all 30 patients in which we attempted transcatheter closure of PMVSD, all patients (100%) were successfully treated by transcatheter intervention. There were 7 male and 23 female patients as shown in figure-1. According to colour Doppler TTE before intervention, the mean +- SD end-diastolic PMVSD size was 4.87 +- 1.32 mm as shown in table-I.

Complications And Troubleshootings

* Aortic regurgitation requiring surgical repair or replacement,

* Device embolizations requiring surgical removalInfective endocarditis.

* Complete atrioventricular block

* Pacemaker implantation

* Residual shunt

* Tricuspid valvular regurgitation

* Death

During median follow-up, 2 adverse events (6%) were reported in patients who underwent attempted VSD closure. One child developed arrhythmia while the sheath was in left ventricle which settled subsequently. The other had weak femoral pulse for few hours which settled with IV heparin.

DISCUSSION

Perimembranous ventricular septal defect is the mostcommon congenital cardiac defect12. Open surgery and the transcatheter technique can achieve reasonably good results in closing aPMVSD13,14. Transcatheter closure has the advantages of reduced psychological impact, less pain, and discomfort due to the procedure, shorter hospital stay, no need for admission to an intensive care unit, faster time to normal activities7. Different devices have been used to close PMVSD15, among which the Amplatzer PMVSD occluder and similar devices have been shown to cause few complications and yield good results16. In our set up we used SHSMA and Occlutech devices for VSD closure. However, long-term follow-up results are lacking with transcatheter device closure as compared to open heart surgery7. This study was designed to evaluate the safety and efficacy of transcatheter closure of PMVSD without AV loop and its intermediate and long-term clinical outcomes.

Adverse events rate was low and no permanent cAVBs was experienced. Careful monitoring of the heart rhythm remains mandatory throughout follow-up due to the severe impact of and the characteristically late onset of cAVB. Valvular regurgitation was another major consideration catheter closure of PMVSD. Impingement of the occluder on the valve leaflets may cause instant aortic or tricuspid regurgitation by interfering with the chordae tendineae17. Thus, Transthoracic echocardiography (TTE) and angiography are crucial for confirming correct device deployment. We experienced no case of valve regurgitation. The mechanism may be associated with improper placement of the occluder on the tricuspid septal leaflets, migration of the occluder, shape memory of nithinol wires, or rupture of the chordae tendineae18. Perimembranous ventricular septal defect involves the entiremembranous septum and adjacent structures and may have many variations.

The aortic valve, tricuspid chordae tendineae, atrioventricular node, conduction bundle are all closely related to the PMVSD. Complications of transcatheter PMVSD closure in our study were negligible. Most adverse events took place in the early stage of the procedure, and only minor events were observed during the follow-up period after discharge. This outcome is quite different from previous reports7,19. The most common complications associated with transcatheter PMVSD closure were heart rhythm disturbances and late appearance of femoral pulse. Other common adverse events included kinking of sheath during device placement which setteled with little pull back of sheath with device. To avoid complications the inclusion/exclusion criteria for transcatheter PMVSD closure should be strict.

Severe aortic valve prolapse, a large VSD with pulmonary hypertension, abnormal tricuspid chordae tendineae origination, and small infants with low body weight should be referred for open surgery and excluded from transcatheter intervention. In our center, more PMVSD patients were referred directly for surgery after TTE screening during the same study period. It is likely due to this strict screening that the success rate of transcatheter PMVSD closure in our group was remarkable. Second, passing the guide-wire and catheter across the defect is a crucial step in transcatheter PMVSD closure9. Different types of guide catheters can be useful in passing through the PMVSD, such as the right Judkins, and partly cut pigtail catheter. Once the guide-wire passes the defect, the route of catheter and guide wire should be properly monitored. Kinking of the sheath should be carefully watched before introducing the device.

Before releasing the device, angiography of the ascending aorta is recommended to determine whether aortic valve insufficiency is present. If new-onset aortic valvular regurgitation is identified, either asymmetric devices or abandonment of the procedure should be considered to prevent severe complications.

CONCLUSION

This study has proved that transcatheter device closure without AV loop is an effective method in treating PMVSD patients with excellent results avoiding many complications in experienced hands. The success rate was high, and the long-term follow-up result was favorable. Adverse events were rare and were generally manageable. The transcatheter approach provides a less-invasive alternative to open surgery and may become the treatment of choice for selected patients with PMVSD.

CONFLICT OF INTEREST

This study has no conflict of interest to declare by any author.

REFERENCES

1. Rahmath MR, Numan M, Dilawar M. Medium to long-term echo follow-up after ventricular septal defect device closure. Asian Cardiovascular and Thoracic Annals 2016; 24(5): 422-7.

2. Mavroudis C. Ventricular septal defect. InAtlas of Pediatric Cardiac Surgery 2015 (pp. 99-115). Springer London.

3. Kung GC, Wong PC. Ventricular Septal Defects. In Transesophageal Echocardiography for Congenital Heart Disease 2014 (pp. 241-252). Springer London.

4. Baro L, Paul T, Chaliha MS, Gogoi A, Kataki RP, Dowerah P. Clinical Spectrum of Ventricular Septal Defect in Children in A Tertiary Care Hospital. Cough 2016; 30: 48: 68.

5. Jortveit J, Leirgul E, Eskedal L, Greve G, Fomina T, Dohlen G, et al. Mortality and complications in 3495 children with isolated ventricular septal defects. Archives of disease in childhood 2016; 101(9): 808-13.

6. Menting ME, Cuypers JA, Opic P, Utens EM, Witsenburg M, van den Bosch AE, van Domburg RT, et al. The unnatural history of the ventricular septal defect: outcome up to 40 years after surgical closure. J Am Coll Cardiol 2015; 65(18): 1941-51.

7. Thanopoulos BD, Rigby ML, Karanasios E, Stefanadis C, Blom N, Ottenkamp J, Zarayelyan A. Transcatheter closure of perimembranous ventricular septal defects in infants and children using the Amplatzerperimembranous ventricular septal defect occluder. Am J Cardiol 2007; 99: 984-89.

8. Xunmin C, Shisen J, Jianbin G, Haidong W, Lijun W. Comparison of results and complications of surgical and Amplatzer device closure of perimembranousventricularseptal defects. Int J Cardiol 2007; 120: 28-31.

9. Qin Y, Chen J, Zhao X, Liao D, Mu R, Wang S, Wu H, Guo H. Transcatheter closure of perimembranous ventricular septal defect using a modified double-disk occluder. Am J Cardiol 2008; 101: 1781-86.

10. Lock JE, Block PC, McKay RG, Baim DS, Keane JF. Transcatheter closure of ventricular septal defects. Circulation 1988; 78: 361-368.

11. Shah SM, Ullah I, Khan MG, Ullah N, Malik A, Khan RA. Frequency of Complete Heart Block After Surgical Closure of Perimembranous Ventricular Septal Defect. J Postgrad Med Inst 2016; 29(4).

12. Butera G, Chessa M, Carminati M. Percutaneous closure of ventricular septal defects. Cardiol Young 2007; 17: 243-53.

13. Zheng Q, Zuo J, Yang J, Wang H, Yu S, Yi D. A comparative study: early results and complications of percutaneous and surgical closure of ventricular septal defect. Cardiology 2009; 238-43.

14. Backer CL. Ventricular septal defect closure: what is the role for transcatheter closure? Cardiology 2009; 114: 235-37.

15. Gu X, Han YM, Titus JL, Amin Z, Berry JM, Kong H, et al. Transcatheter closure of membranous ventricular septal defects with a newnitinol prosthesis in a natural swine model. Catheter Cardiovasc Interv 2000; 50: 502-09.

16. Hijazi ZM, Hakim F, Al-Fadley F, Abdelhamid J, Cao QL. Transcatheter closure of single muscular ventricular septal defects using the amplatzer muscular VSD occluder: initial results and technical considerations. Catheter CardiovascInterv 2000; 49: 167-72.

17. Sullivan ID. Transcatheter closure of perimembranous ventricular septal defect: is the risk of heart block too high a price? Heart 2007; 93: 284-86.

18. Szkutnik M, Qureshi SA, Kusa J, Rosenthal E, Bialkowski J. Use of the Amplatzer muscular ventricular septal defect occluder for closure of perimembranousventricularseptal defects. Heart 2007; 93: 355-58.

19. Chessa M, Butera G, Negura D, Bussadori C, Giamberti A, Fesslova V, Carminati M. Transcatheter closure of congenital ventricular septal defects in adult: mid-term results and complications. Int J Cardiol 2009; 133: 70-3.

20. Butera G, Carminati M, Chessa M, Piazza L, Micheletti A, Negura DG, et al. Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol 2007; 50: 1189-95.
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pakistan Armed Forces Medical Journal
Date:Feb 28, 2019
Words:2743
Previous Article:COMPARISON OF TROPONIN I WITH CK-MB AND ECG FOR PREDICTING CLINICALLY SIGNIFICANT MYOCARDIAL INJURY AFTER CORONARY ARTERY BYPASS GRAFTING.
Next Article:EXPERIENCE OF ATRIAL SEPTAL DEFECT DEVICE CLOSURE IN PATIENTS MORE THAN FIFTY YEARS OF AGE.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters